Skip to main content
. Author manuscript; available in PMC: 2022 Sep 7.
Published in final edited form as: Lancet Microbe. 2021 Dec 6;3(2):e113–e123. doi: 10.1016/S2666-5247(21)00235-4

Figure 6. Correlation between gene expression profiles and ZEBOV-GP-specific antibody titres in response to rVSVΔG-ZEBOV-GP vaccination in cohorts from Geneva, USA, Lambaréné, and Kilifi and reactogenicity (arthritis) in the Geneva cohort.

Figure 6

(A) Volcano plot showing genes that significantly correlate with ZEBOV-GP-specific antibody titres in all cohorts using random-effects meta-analyses (p<0·05). (B) Heatmap showing the Spearman’s rank correlation coefficient of the genes included in the five-gene signature (p<0·05) that correlates with the ZEBOV-GP-specific antibody titres. (C) The receiver operating characteristic curves show the predictive power of the identified five-gene signature to classify participants at day 1 into those that will and those that will not develop arthritis in training and test set using the regularised logistic regression model. The curves display the values extracted from the regularised logistic regression model after hyperparameters adjustments. AUC=area under the receiver operating characteristic curve. IFITM1/3=IFITM1 or IFITM3, or both. rVSVΔG-ZEBOV-GP=recombinant vesicular stomatitis virus vector expressing the Zaire Ebola virus glycoprotein. ZEBOV-GP=Zaire Ebola virus glycoprotein.